NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
CERETEC (technetium tc-99m exametazime) by GE HealthCare is radiopharmaceutical activity [moa]. Approved for radioactive diagnostic agent [epc]. First approved in 1988.
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CERETEC is a radiopharmaceutical diagnostic agent containing technetium Tc-99m exametazime, used for brain imaging to assess cerebral blood flow and detect abnormalities in neurological conditions. It works by binding to red blood cells and localizing in the brain, allowing physicians to visualize regional cerebral perfusion patterns via nuclear imaging.
LOE Approaching
As a mature diagnostic radiopharmaceutical approaching loss of exclusivity, CERETEC represents a stable but contracting portfolio asset with diminishing team investment.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications (1)
Career Relevance
Working on CERETEC offers stability in a mature diagnostic asset with deep market penetration but limited growth trajectory. Career advancement on this product is best suited for professionals focused on lifecycle management, market access, and operational efficiency rather than launch momentum or clinical innovation.
Worked on CERETEC at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.